Michael J. Morris, MD, discusses the design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.
Michael J. Morris, MD, medical oncologist, clinical director of Genitourinary Medical Oncology Service, and Prostate Cancer Section Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.
The study evaluated the investigational, urea-based prostate specific membrane antigen (PSMA)-targeted PET radiopharmaceutical 18F-DCFPyL-PET/CT, says Morris.
Eligible patients had to have biochemically relapsed disease following radical prostatectomy or definitive radiation therapy, Morris explains.
Historically, this has been a challenging patient population to study because patients need to have negative standard imaging. In this trial, patients had to undergo standard imaging with a CT scan, MRI, bone scan, or fluciclovine to obtain negative or noninformative results prior to enrollment, Morris explains.